Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hi Bob,DNDT-Doesn't the extension give 15 days to file an annual report and 5 days to file a quarterly report?Thanks Jerry
GNBT & Hutchinson Cancer ResearchCenter
by: docriedenschneider (59/M/Los Angeles)
Long-Term Sentiment: Strong Buy 04/08/05 01:34 pm
Msg: 12066 of 12069
http://www.antigenexpress.com/news_release.asp?NewsID=35
The rearcher at Hutchinson, Cassian Yee, is absolutely first rate, indicating the GNBT science must be very good indeed:
http://myprofile.cos.com/cassian
GNBT That was three different exercise of 100,000 share options.Still going strong. They are ready to start selling oral inhaler in S.America
GNBT with insiders buying! 300k insider buys of common link here
by: neveraloss28 04/07/05 04:16 pm
Msg: 11985 of 11989
http://10kwizard.ccbn.com/fil_list.asp?TK=GNBT&CK=&FG=0&alld=ON&BK=DEDEAD&FC=636 363&LK=660066&AL=000000&VL=660066&TC1=DEDEAD&TC2=DEDEAD&SC=ON&DF=OFF&FT[]=227&FT []=231&FT[]=228&FT[]=236&FT[]=229&FT[]=284&FT[]=237&FT[]=319&SEC16=OFF
jasonak,I have added another 15k of CGCP over the last week or 2.One of my largest holdings!
Generex Biotechnology Establishes Regulatory Compliance Committee
Thursday April 7, 8:30 am ET
- Company Continuing Its Preparations for the Pending Commercialization of Oral-lyn(TM)
TORONTO, April 7 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT - News), a leader in the area of buccal drug delivery, reported today that its board of directors has established a Regulatory Compliance Committee comprised of two of the Company's independent directors, Mindy Allport-Settle and Peter Amanatides (chair). The function of this new committee will be regulatory oversight in respect of the forthcoming scale-up of the Company's manufacturing facilities and those of PharmaBrand S.A., the Company's South American co-venture partner, in anticipation of the initial commercialization of Oral-lyn(TM), the Company's flagship oral insulin spray formulation. Generex is taking a proactive approach to ensure that it maintains compliance with the requirements of regulatory agencies so that quality and reliability of supply will be assured and time-to-market will be reduced as Oral-lyn(TM) is introduced in new jurisdictions.
ADVERTISEMENT
"We are actively preparing for the commercial launch of Oral-lyn(TM)," said Rose Perri, the Company's Chief Operating Officer, "and we are pleased that Ms. Allport-Settle and Mr. Amanatides have agreed to make their considerable pharmaceuticals regulatory experience available to us as we ramp up the manufacturing facilities."
Ms. Allport-Settle is the President & Chief Executive Officer of Integrated Development, LLC (www.integradev.com) and a Vice-President of Impact Management Services, Inc. (www.impactserv.com), both independent consulting firms to the pharmaceuticals industry, providing informed guidance in operational, project and contract management, new business development and regulatory compliance. Ms. Allport-Settle has worked with companies such as GlaxoSmithKline, Pfizer, AstraZeneca, Johnson Controls and DSM Pharmaceuticals. She is the author of LAMPS: Linked Activity Management Planning System (2005), CCIS: Corporate Compliance Initiative System (2005) (project design and management for establishing regulatory compliance) and is the creator of the Integrated Development Training System (a training system that assists pharmaceutical companies achieve their regulatory compliance goals). She is currently working on her Masters Degree in Business Administration in Global Management at the University of Phoenix.
In addition, Ms. Allport-Settle recently completed Harvard Business School's executive education program Compensation Committees: Preparing for the Challenges Ahead. The program provides an in-depth examination of the root causes of many compensation issues and possible solutions for the difficulties faced by companies and their boards. The program helps directors to understand shareholder and regulatory concerns about executive compensation; identify and address the underlying causes of those concerns; define the characteristics of a well-functioning compensation committee; and become aware of the challenges that compensation committees are facing. The program is developed and taught by Harvard Business School faculty who are distinguished academicians, skilled educators, groundbreaking researchers, award-winning authors, and entrepreneurs, including Jay W. Lorsch, V.J. Narayanan, and Krishna G. Palepu. Ms. Allport-Settle is the chairperson of the Company's Compensation Committee.
Mr. Amanatides, who was elected to the Generex board of directors as an independent member at the annual stockholders' meeting on April 5, 2005, has more than 15 years' work experience in the pharmaceutical and biotechnology industries. He is the President & Chief Operating Officer of Pharmalogika, Inc., an organization that helps companies in the pharmaceutical and biotechnology industries navigate through all phases of the drug lifecycle, from discovery through commercialization. Since August, 2004 he has been interim Vice-President, Quality Operations for the DSM Biologics division of DSM Pharmaceutical Products, Inc., responsible for preparing a biopharmaceutical products manufacturing facility for commercial contract manufacturing, including quality assurance, regulatory, validation, change control and document control, and training. From April, 2002 to August, 2004 he was a Director of Quality Assurance Support & Training at DSM, with QA oversight for one of the largest contract manufacturing facilities in the world supplying oral and topical dosage forms, sterile products and active pharmaceutical ingredients. From February, 1999 to April 2002, Mr. Amanatides was Director of Quality Systems for Celera Genomics. Mr. Amanatides holds a Master of Science degree in biotechnology and molecular biology and is an American Society for Quality Certified Quality Manager.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral- lyn(TM)), is in various stages of clinical trials around the world.
For more information, visit the Generex Web site at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward- looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
--------------------------------------------------------------------------------
Source: Generex Biotechnology Corporation
Added another 5k of MKRS today @.21
ksuave,I added another 5k of MKRS today @.21
My top holdings: PDGE CGCP DNDT MKRS TMY ASPN GNBT PVCT
Yes alot in the last 5 min.on DNDT DND TECHNOLOGIES INC - Nasdaq National Market: DNDT
Time & Sales most recent next page
Rec. Time Action Price Volume
3:59:26 PM Trade 0.34 5000
3:59:24 PM Bid 0.3 5000
3:59:18 PM Ask 0.34 5000
3:59:18 PM Bid 0.32 5000
3:58:44 PM Trade 0.34 2500
3:58:44 PM Ask 0.35 5000
3:58:26 PM Trade 0.335 4000
3:58:20 PM Trade 0.34 2500
3:57:50 PM Ask 0.36 5000
3:57:32 PM Trade 0.34 5000
3:57:12 PM Bid 0.34 5000
3:57:10 PM Bid 0.33 5000
3:57:08 PM Bid 0.32 5000
3:57:06 PM Bid 0.31 5000
3:57:06 PM Bid 0.3 5000
3:57:04 PM Bid 0.29 5000
3:55:50 PM Ask 0.37 5000
3:55:48 PM Trade 0.34 5530
3:55:24 PM Trade 0.3099 6000
3:55:22 PM Ask 0.34 5000
3:55:18 PM Trade 0.31 5000
DNDT .30/.33 Earnings Thursday,I think?????Should be very good!
EGSR looking more & more like a POS
OT-Barry Bonds' ex-girlfriend told a grand jury in San Francisco last week the Giants outfielder confided to her in 2000 that be began using steroids, two sources told the San Francisco Chronicle for Sunday's editions.
Kimberly Bell, 35, was subpoenaed by the prosecutors in the BALCO case and testified for about two hours with full immunity from prosecution, her attorney told The Chronicle.
"It's clear from the subpoena that they are looking at Barry Bonds and the possibility he may have given untruthful testimony to the grand jury," Hugh Levine, Bell's attorney, told The Chronicle.
In December 2003, Bonds testified to a grand jury that he used a clear substance and a cream given to him by a trainer who was indicted in a steroid-distribution ring, but said he didn't know they were steroids, the San Francisco Chronicle reported.
Bonds told a U.S. grand jury that he used undetectable steroids known as "the cream" and "the clear," which he received from personal trainer Greg Anderson during the 2003 season. According to Bonds, the trainer told him the substances were the nutritional supplement flaxseed oil and a pain-relieving balm for the player's arthritis.
According to The Chronicle, Bell told the grand jury that she dated Bonds from 1994-2003 and that the outfielder gave her $80,000 in cash for the down payment on a house in Scottsdale, Ariz., near the Giants' spring training facility. She claims that Bonds earned the money from sales of autographed baseballs and memorabilia.
Bonds' attorney, Michael Rains, told The Chronicle that the slugger had never used banned substances and had never given cash to Bell.
Rains claims that Bell's subpoena is further proof that the real target of the BALCO inquiry is Bonds.
"It's always been the U.S. versus Bonds, and they're always just gunning for the big guy," he told The Chronicle.
The Chronicle reported Rains wrote five letters between Oct. 14, 2003, and March 11, 2004, in which he acknowledged that Bell and Bonds had a long romantic relationship. Rains denied that Bonds had promised to buy Bell a house in those letters.
The Chronicle reported the breakup between Bell and Bonds was followed by a dispute over the house in Scottsdale. According to legal correspondence reviewed by The Chronicle, Bell threatened to sue Bonds for not paying off the house. Rains charged Bell with trying to extort money from the Giants slugger. The Chronicle reported Bell dropped the idea of a lawsuit in favor of writing a memoir about her experience.
The lead agent in the BALCO case, IRS investigator Jeff Novitzky, contacted Bell after she appeared with Geraldo Rivera on the Fox News Channel to talk about Bonds' alleged steroid use and to promote her own book project.
Bell told the grand jury that Bonds revealed his steroid use while discussing an elbow injury he suffered in 1999, according to The Chronicle. Bonds underwent surgery on April 21, 1999 to repair a torn triceps tendon and to remove a bone spur.
"He told me that steroids had probably caused the injury and that he would have to be more careful in the future," Bell said, according to The Chronicle.
U2 I'll be at MSG in N.Y. 5/21 Rattle and Hum
Mold is becoming one of the Scariest words in the Insurance buisness!They hear the word MOLD & money is no expense to have it fixed!I had a leak in the master bathroom & it may have been their for up to 3 weeks.Insurance was only going to pay to have the wall & plumbing fixed.Mentioned MOLD & they paid for a whole new bathroom upstairs, sheetrock & new carpets down stairs.
Just added 2500 PDGE @ 1.48 Thanks
Ist time Poster??????????????Who could this be???????
CGCP i expect this to be around a buck or higher in 3months.My avg is in the high 50's & haven't sold a share.Good Luck Jerry
Some buyers showing up now! CGCP .73/.74From 5 mms @.70 to 9 now
Miller analyst from Smith Barney C.C. CGCP Question: can top-line revenues grow to $30-$50M, and company answer is unequivocably yes...will see more cardiologists refer patients for minimally invasive procedures going forward.
"Seeing a phenomenal amount of interest
hitpicker-CGCP - .72 Earnings as they promised:
Cardiogenesis Reports 2004 Fourth Quarter, Year End Results Annual Operating Income Reported for First Time in 16 Year Company History
Thursday March 3, 7:30 am ET
- Company Posts 52% Increase in Quarter-to-Quarter Revenue and 14% Increase in Year-to-Year Revenue
http://biz.yahoo.com/prnews/050303/lath045_1.html
CGCP - .72 Earnings out!
Cardiogenesis Reports 2004 Fourth Quarter, Year End Results Annual Operating Income Reported for First Time in 16 Year Company History
Thursday March 3, 7:30 am ET
- Company Posts 52% Increase in Quarter-to-Quarter Revenue and 14% Increase in Year-to-Year Revenue
http://biz.yahoo.com/prnews/050303/lath045_1.html
Morning all,CGCP - .72 Earnings as they promised:
Cardiogenesis Reports 2004 Fourth Quarter, Year End Results Annual Operating Income Reported for First Time in 16 Year Company History
Thursday March 3, 7:30 am ET
- Company Posts 52% Increase in Quarter-to-Quarter Revenue and 14% Increase in Year-to-Year Revenue
http://biz.yahoo.com/prnews/050303/lath045_1.html
CGCP - .72 Earnings as they promised:
Cardiogenesis Reports 2004 Fourth Quarter, Year End Results Annual Operating Income Reported for First Time in 16 Year Company History
Thursday March 3, 7:30 am ET
- Company Posts 52% Increase in Quarter-to-Quarter Revenue and 14% Increase in Year-to-Year Revenue
http://biz.yahoo.com/prnews/050303/lath045_1.html
CGCP .72 Cardiogenesis Sets Date for 2004 Fourth Quarter and Year-End Results Announcement and Conference Call
Monday February 7, 7:30 am ET
FOOTHILL RANCH, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (OTC Bulletin Board: CGCP - News), the market leader in surgical products and accessories used in angina-relieving Transmyocardial Revascularization (TMR) and Percutaneous Myocardial Channeling (PMC) procedures, announced that it will release its financial results for the fourth quarter and year-ended December 31, 2004, before the market opens on Thursday, March 3, 2005. That same day, at 12:30 p.m. EST (9:30 a.m. PST), Cardiogenesis' senior management will host a conference call which will be broadcast live over the Internet to discuss the Company's results for the quarter and comment on the current progress of the business.
Those interested in listening to the live webcast of the conference call may do so by going to the Company's website at www.cardiogenesis.com. Webcast participants are encouraged to go to the website at least 15 minutes prior to the start of the call to register and, if necessary, download any needed audio software. A replay of the call will also be accessible at www.cardiogenesis.com for seven days starting shortly after the live webcast.
About Cardiogenesis Corporation
Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that stimulate cardiac angiogenesis. The Company's market leading Holmium: YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease. Surgical products and accessories for the Company's minimally invasive Percutaneous Myocardial Channeling (PMC) procedure are currently being marketed in Europe and other international markets.
For more information on the Company and its products, please visit the Cardiogenesis web site at www.cardiogenesis.com.
With the exception of historical information, the statements set forth above include
GNBT-Webcast Alert: Generex Biotechnology Corporation Presentation at Informed Investors Small Cap / Growth Virtual Forum to be Webcast on March 3, 2005, 11:00 am ET
Wednesday March 2, 8:30 am ET
TORONTO--(BUSINESS WIRE)--March 2, 2005--Generex Biotechnology Corporation (NASDAQ: GNBT - News) will present at the following forum:
What: Generex Biotechnology Corporation (Nasdaq: GNBT - News) will give
a presentation at Informed Investors Small Cap / Growth
Virtual Forum.
When: Thursday, March 3, 2005 @ 11:00 AM Eastern Time
Where: http://www.informedinvestors.com/IIF_Forum.asp?ForumID=89458
How: Live over the Internet--Simply log on to the web at the
address above.
Contact: Zack Noory, Investor Relations Representative, (818)382-9718,
znoory@irintl.com
If you are unable to attend the live event, the forum will be available via webcast at
http://www.informedinvestors.com/IIF_Forum.asp?ForumID=89458
Generex Biotechnology Corporation is engaged primarily in the research and development of drug delivery technologies. The Company's primary focus is the development of its technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. The Company's buccal delivery technology involves the preparation of a formulation in which an active pharmaceutical agent is placed in a solution with a combination of absorption enhancers and other excipients classified generally recognized as safe (GRAS) by the United States Food and Drug Administration (FDA) when used in accordance with specified quantity and other limitations. The resulting formulation is aerosolized with a pharmaceutical grade chemical propellant and is administered to the patient using the Company's RapidMist device.
--------------------------------------------------------------------------------
Contact:
FORUM CONTACT:
Cary Loeser, Informed Investors, 804-327-3407
cloeser@wilink.com
http://www.informedinvestors.com
Hitpicker it should be a good day!
CGCP looking ripe! .71/.72 CGCP Fourth Quarter Revenue Highest(C.Call tomorrow) in Last Four Years; Positive Operating Results Expected for Both Fourth Quarter and 2004
FOOTHILL RANCH, Calif., Jan. 18 /PRNewswire-FirstCall/ -- CardioGenesis Corporation (OTC Bulletin Board: CGCP - News), the market leader in surgical products and accessories used in angina-relieving Transmyocardial Revascularization (TMR) and Percutaneous Myocardial Channeling (PMC) procedures, today announced that fourth quarter and 2004 annual revenues are expected to be at their highest level in the last four years. Strong TMR handpiece sales combined with laser sales in the fourth quarter resulted in expected revenues in the range of $4.9 - $5.1 million for the fourth quarter and $15.2 - $15.4 million for the year. These results reflect an estimated 80% quarter-to-quarter increase in revenues from the 2004 third quarter, a 48% increase in revenues compared to Q4 of 2003, and a 14% year-to-year increase in revenues from the prior year.
Hi Merci!CGCP maybe today it shows a little life? Earnings thursday before the bell.
Any thoughts on CGCP,earnings before the bell thursday.CC at 12.30 in the afternoon. CardioGenesis Announces Preliminary Fourth Quarter, Year End Results
Tuesday January 18, 7:32 am ET
Fourth Quarter Revenue Highest in Last Four Years; Positive Operating Results Expected for Both Fourth Quarter and 2004
FOOTHILL RANCH, Calif., Jan. 18 /PRNewswire-FirstCall/ -- CardioGenesis Corporation (OTC Bulletin Board: CGCP - News), the market leader in surgical products and accessories used in angina-relieving Transmyocardial Revascularization (TMR) and Percutaneous Myocardial Channeling (PMC) procedures, today announced that fourth quarter and 2004 annual revenues are expected to be at their highest level in the last four years. Strong TMR handpiece sales combined with laser sales in the fourth quarter resulted in expected revenues in the range of $4.9 - $5.1 million for the fourth quarter and $15.2 - $15.4 million for the year. These results reflect an estimated 80% quarter-to-quarter increase in revenues from the 2004 third quarter, a 48% increase in revenues compared to Q4 of 2003, and a 14% year-to-year increase in revenues from the prior year.
ADVERTISEMENT
The Company also announced the highest level of handpiece sales in eight quarters with handpiece sales exceeding 800 units in the fourth quarter. Laser sales were also robust in the fourth quarter with 11 units sold. The FDA approval in late December of the SolarGen 2100s provided the Company with the opportunity to sell three SolarGen 2100s units in December. Chairman and CEO, Michael J. Quinn commented, "Customer reactions to our advanced TMR PLUS Platform and SolarGen 2100s have been very positive."
"The 2004 fourth quarter results reflect the positive impact of the Company's actions over the last 12 months. From the new business unit structure established at the beginning of the year, the sales force expansion, the completion of $8.7 million in financing and the recent FDA approval of the SolarGen 2100s, several important milestones were achieved in 2004," Quinn stated. "We focused our sales force on our core TMR business, and our entire organization on the advanced products supporting the launch of our TMR PLUS platform, which contributed directly to an increased acceptance of TMR in the surgical community. We also strengthened our balance sheet, positioning us with the resources to continue to expand our product pipeline and build a substantially larger and more profitable company."
Wish i had some more cash today,could have added more before thursday! http://biz.yahoo.com/prnews/050118/latu055_1.html
Need to get an overnight on that flyer. lol
I got my AZGS flyer today,looks like alot people got there flyer last wed. or thursday! lol http://finance.yahoo.com/q/bc?s=AZGS.OB&t=5d
Added more CGCP @.62 today.
Bought some more CGCP this morning @.62 Fourth Quarter Revenue Highest in Last Four Years; Positive Operating Results Expected for Both Fourth Quarter and 2004 will be out Thursday before the opening bell.
http://biz.yahoo.com/prnews/050118/latu055_1.html
The list, at http://www.nasdaqtrader.com/aspx/regSHO.aspx , purportedly lists
all those companies, for which over a period of five consecutive settlement
days, there are aggregate "fails to deliver" at a registered clearing
agency of 10,000 shares or more, and the levels of fails is equal to at least
1/2 of 1% of the issuer's total shares outstanding. The site has recently begun
listing additional securities under separate spreadsheets, further confusing the
true numbers.
The list, which is the latest in the ever-widening Stockgate scandal, has
created some controversy, with hundreds of stock symbols disappearing since the
initial posting in mid-January, 2005, and with many detractors claiming the list
is barely the tip of the iceberg, missing hundreds of companies that have been
subjected to alleged naked SHOrt selling, as well as not consistent with a
paper, "Strategic Delivery Failures in U.S. Equity Markets" published
under the aegis of the SEC.
The referenced working paper by University of New Mexico Professor Leslie Boni
was initiated while the author was visiting financial economist at the SEC.
She termed the "failures to deliver," which litigants have called
"counterfeiting," as being "pervasive."
The professor said that a whopping 42% of listed stocks at the New York Stock
Exchange, NASDAQ and AMEX, and 47% of unlisted stocks in the OTCBB and Pink
Sheets had persistent fails of 5 days or more with 4% being above the SEC's
threSHOld limits for failures.
The economist pointed to a study conducted by Evans, Geczy, Musto, and Reed in
2003 that provided evidence that while the SRO's have buy-in requirements, such
buy-ins almost never occur. She noted that an audit of one market maker SHOwed
that all or a portion of shares in 69,063 transactions during 1998-1999 were
"fails to deliver."
"The market maker was bought-in on only 86 of these positions," she
stated.
Yet NASDAQ (OTCBB: NDAQ) was recently listing only 123 companies on the NASDAQ,
OTCBB and Pink Sheets, which together comprise the overwhelming bulk of public
companies traded in the U.S. The list changes to some degree each day.
The original list had identified 520 securities, including the stocks of 57
recent PIPE issuers, according to The PIPES Report, in an article headlined
"SHO What?." That list had 379 traded on the NASDAQ, Bulletin Board and
Pink Sheet markets, 68 on the AMEX and 73 traded on the NYSE.
The report quoted Merrill Lynch (NYSE: MER) global equity trading specialist
Mary Ann Bartels of suggesting "increased volatility" and "extended
rallies" in small and mid cap stocks could result, Rhodes Analytics
highlighted 33 NYSE and 63 NASDAQ "dangerous SHOrts" which analyst Bill
Rhodes believed are "vulnerable to squeezes which could last through the
middle of February, when the initial phase of Reg SHO-mandated buy-ins of
threSHOld stocks are expected to peak?"
But a funny thing happened. The 379 NASDAQ threSHOld stocks included only 24
bulletin board stocks, along with 56 NASDAQ-traded stocks and a whopping 254
Pink Sheet quoted stocks, which the Dow Jones (NYSE: DJ) Newswires was quoted as
saying happened to be "every fully-reporting company traded on the Pink
Sheets."
Professor Boni's report SHOwed that "during three random market days inlate
2003 and early 2004 that almost 60% of the stocks on the Bulletin Board and Pink
Sheets had persistent settlement failures," according to The PIPES Report.
"Among the 1,790 OTCBB and Pink Sheet stocks with failures, the average
level of delivery failures equaled 1.56% of outstanding shares ' almost three
times the level that would trigger threSHOld status under Regulation SHO."
In a December 13 conference call, Richard Bernstein, Bear Stearns' (NYSE BSC)
senior managing director of operations, told the firm's brokers that almost 800
OTCBB and Pink Sheet securities would exceed threSHOld levels.
Although every single reporting Pink Sheet stock was listed, the list included
less than 1% of the 3,200 Bulletin Board companies. And several de-registered
companies with no trading activity were also inexplicably included.
I don't really think the list is complete," Jeffrey Meyerson, vice president
at Crown Financial was quoted as saying. "I don't think they got everything
done in time for the deadline."
For an explanation, an SEC spokesperson told The PIPES Report to check with
NASDAQ, and NASDAQ pushed off queries to the NASD, who just didn't respond."
An even bigger surprise than the lack of suspect companies on the list, however,
was the sudden disappearance of 270 stocks in one day, including all but one on
the Pink Sheets and all but nine now on the OTCBB, which, according to The PIPES
Report, suggests "that a settlement crisis several years in the making,
affecting the most under-regulated and least compliant sector of the public
equity markets, had been resolved in less than a week without executing a single
mandatory buy-in."
General Electric's (NYSE: GE) NBC Dateline, which is purportedly preparing a
major expose of the Depository Trust and Clearing Corp., and the alleged almost
$1 billion in "borrowed" ' some say counterfeited" ' certificates
that have reportedly been lent out above the legal issued shares by hundreds of
companies, and the Christian, Smith, Wukoson and Jewell, and OQuinn, Laminack
and Pirtle legal challenges being filed for dozens of such companies, is also
reportedly looking into the threSHOld securities that can only be described as
"missing in action."
In an appearance now archived on StreetSignals (http://www.streetsignals.com),
Christian/O'Quinn legal expert C. Austin (Bud) Burrell, said that the firms have
filed some 15 actions, including key formative lawsuits for Sedona Corp. (OTCBB:
SDNA), NanoPierce Technologies (OTCBB: NPCT), Datascension Inc (OTCBB: DSEN),
Eagle Tech Communications (OTC: EATC) and Hyperdynamics (OTCBB: HYPD)
Burrell said the lawsuits allege a vast conspiracy to manipulate all stocks, and
"provide substantive proof of manipulation." He said that the suits
allege 7,500 companies have been bankrupted since November, 2000, by illegal
naked SHOrtselling and conspiratorial manipulations, resulting in a loss of $17
trillion in market cap, "greater than all the losses in the 1929 market
crash."
He said that shares are electronically counterfeited by the stock borrow program
which the Depository Trust and Clearing Corp., owned by the New York Stock
Exchange and the NASD, acquired in its purchase of National Stock Clearance, and
then misused its "stock borrow program" to create, through its
"nominal ownership provisions," a no-limit "and illegal"
hypothecation system that results in revenues of almost $1 billion annually.
He said naked SHOrt sales were outlawed by Sections 5 and 6 of the 33 Securities
Act, due to their contribution to the '29 Wall Street Crash, which was followed
by ten years of depression.
Burrell told the StreetSignals audience that the DTC "nominally owns $22
trillion in stocks and bonds." He said it even lends out certificates
acquired via ERISA and retirement accounts that are "not eligible" for
such lending, and is a violation of Federal Reserve margin rules.
He said the failures of oversight by the SEC and the Congress in this matter are
massive, and continue to contribute to overseas money laundering, organized
crime, and financing of terrorism.
The threSHOld list as present constituted is both "unexplained and
unexplainable," added Burrell. He alleged that "the SEC instructed the
NASD to remove Pink Sheet stocks from the list," and criticized them for
their lack of transparency or explanation.
For up-to-the-minute news, features and links click on
http://www.financialwire.net
FinancialWire is an independent, proprietary news service of Investrend
Information, a division of Investrend Communications, Inc. It is not a press
release service and receives no compensation for its news or opinions. Other
divisions of Investrend, however, provide shareholder empowerment platforms such
as forums, independent research and webcasting. For more information or to
receive the FirstAlert daily summary of news, commentary, research reports,
webcasts, events and conference calls, click on
http://www.investrend.com/contact.asp
The FinancialWire NewsFeed is now available in multiple formats to your site or
desktop, free. Click on: http://www.investrend.com/XmlFeeds?level=268
Anyone with a take on GNBT,Alot on the bid the whole week but no movement? tks http://stockcharts.com/def/servlet/SC.web?c=gnbt
You're welcome )
Mikros Systems CorporationUt .19/.20 (the "Company") was founded in 1978 in Albany, New York. The Company's headquarters are located at 707 Alexander Road, Suite 208, Princeton, New Jersey; telephone (609)987-1513.
Initially, the Company supplied technology for military applications. The related knowledge base and proprietary technology developed was recognized as applicable to the rapidly expanding wireless business in the commercial sector.
In 1995, the Company's Board of Directors decided the Company should pursue commercial contracts which would employ advanced techniques to enhance the data transmission rates in the AM and FM radio spectrum. Since the Company had limited resources, it was decided to pursue the AM technology.
In 1996, Safeguard Scientifics (Delaware), Inc., (Safeguard) invested $1,000,000 in the Company in exchange for 10% ownership in the Company. At the same time, Mobile Broadcasting Corporation (MBC) was created to exploit the AM radio technology, particularly in mobile or portable platforms such as automobiles. Initially, Safeguard invested $1,000,000 in MBC for 75% ownership and the Company owned the remaining 25%. The Company's share in MBC was subsequently increased to 50% as a result of the Company's investment in the development of this technology.
3D was founded in 1996 as a part of the Company's agreement with Safeguard Scientific and retained ownership of the AM and FM technology. 3D had licensed the FM technology rights in North America to the Company and the AM technology rights in North America to MBC. Mikros owned two-thirds of 3D and Safeguard owned the remaining one-third.
In May 2002, the Company entered into a phase I research contract with the Naval Surface Warfare Center in Dahlgren, Virginia. This contract was designed to help fund the development of a certain technology to be utilized by the U.S. Department of Defense. This contract provided for research funding of approximately $100,000 in 2002 and 2003.
In November 2002, Safeguard Scientifics sold its equity interests in MBC, 3D and the Company to Paul G. Casner, Thomas Lynch, Thomas J. Meaney, Wayne E. Meyer and Tom L. Schaffnit, each of whom is a Director of the Company. Mr. Meaney also is President, Chief Executive Officer and Chief Financial Officer of the Company. Each of such individuals acquired from Safeguard Scientifics (Delaware), Inc. 382,400 shares of the Company's Common Stock and warrants to purchase 1,091,800 shares of Common Stock. In January 2003, Messrs. Casner, Lynch, Meaney, Meyer and Schaffnit each contributed the equity interests of MBC and 3D to the capital
of the Company. Upon this contribution, MBC and 3D became wholly owned subsidiaries of the Company, and these subsidiaries were subsequently dissolved in 2003.
In 2003, the Company's only revenues were generated from Phase I and II research contracts with the Naval Surface Warfare Center in Dahlgren, Virginia. The Phase II contract was entered into on August 8, 2003 and is expected to continue through the first quarter of 2005. The contract provided for initial research funding of $150,000, which was later increased to $600,000. The contract also provides for supplemental funding of up to $150,000, at the option of the issuer. The Contract is cost plus a fixed fee contract and the Company is billing its actual costs on a bi-weekly basis. As of September 30, 2004, the Company had billed $662,787 under this phase II contract.
In June 2004, the Company was awarded a Small Business Innovation Research (SBIR) Phase I contract from the Office of Naval Research valued at approximately $100,000, the contract is for researching and evaluating techniques to minimize interference between the U.S. Navy radar and wireless communication systems.
In September 2004, the Company was awarded a Small Business Innovation Research (SBIR) Phase III contract from the Naval Surface Weapons Center Dahlgren, VA valued at approximately $2,400,000, the contract is to complete the development and to begin initial production of an intelligent test tool for Navy radars. The Multi-Function Distributed Analysis Tool MFDAT) has been designed by the Company under a $1,000,000 SBIR Phase II contract, which began in August 2003.
SWTX Ut in pm